Winslow Asset Management Inc. Purchases 385 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Winslow Asset Management Inc. boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,262 shares of the medical research company’s stock after purchasing an additional 385 shares during the quarter. Bio-Rad Laboratories comprises about 1.5% of Winslow Asset Management Inc.’s portfolio, making the stock its 24th biggest position. Winslow Asset Management Inc. owned 0.09% of Bio-Rad Laboratories worth $8,118,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Van ECK Associates Corp bought a new position in shares of Bio-Rad Laboratories during the second quarter valued at approximately $180,040,000. First Eagle Investment Management LLC lifted its holdings in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after buying an additional 634,311 shares during the period. Dimensional Fund Advisors LP boosted its position in Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after acquiring an additional 193,700 shares in the last quarter. Select Equity Group L.P. increased its holdings in shares of Bio-Rad Laboratories by 26.2% in the 2nd quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock valued at $177,391,000 after acquiring an additional 134,856 shares during the period. Finally, Earnest Partners LLC raised its position in shares of Bio-Rad Laboratories by 30.8% in the 1st quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company’s stock worth $178,091,000 after acquiring an additional 121,272 shares in the last quarter. 65.24% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Andrew J. Last sold 3,000 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Citigroup lifted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Royal Bank of Canada increased their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $365.97 on Tuesday. The firm has a market capitalization of $10.25 billion, a P/E ratio of -13.39 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average price of $339.08 and a 200 day moving average price of $312.54.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same period in the previous year, the firm posted $2.33 earnings per share. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.